vTv Therapeutics Terminates Material Agreement
Ticker: VTVT · Form: 8-K · Filed: Oct 25, 2024 · CIK: 1641489
| Field | Detail |
|---|---|
| Company | Vtv Therapeutics Inc. (VTVT) |
| Form Type | 8-K |
| Filed Date | Oct 25, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement-termination, 8-k
Related Tickers: VTVT
TL;DR
vTvT terminated a big deal, filing today.
AI Summary
vTv Therapeutics Inc. announced on October 22, 2024, the termination of a material definitive agreement. The company, incorporated in Delaware, filed this 8-K report on October 25, 2024, detailing this significant event.
Why It Matters
The termination of a material definitive agreement can significantly impact a company's operations, financial standing, and future strategic direction.
Risk Assessment
Risk Level: medium — Termination of a material agreement often signals significant business challenges or strategic shifts that could affect the company's future performance.
Key Numbers
- 001-37524 — SEC File Number (Identifies the company's filings with the SEC.)
- 47-3916571 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- vTv Therapeutics Inc. (company) — Registrant
- October 22, 2024 (date) — Date of earliest event reported
- October 25, 2024 (date) — Filing date
- Delaware (jurisdiction) — State of incorporation
FAQ
What specific material definitive agreement was terminated by vTv Therapeutics Inc.?
The filing states the termination of a material definitive agreement but does not specify which agreement was terminated.
What is the effective date of the termination of the material definitive agreement?
The earliest event reported, which is the termination of the material definitive agreement, occurred on October 22, 2024.
When did vTv Therapeutics Inc. file this 8-K report?
vTv Therapeutics Inc. filed this 8-K report on October 25, 2024.
In which state is vTv Therapeutics Inc. incorporated?
vTv Therapeutics Inc. is incorporated in Delaware.
What is the principal executive office address for vTv Therapeutics Inc.?
The principal executive offices are located at 3980 Premier Drive, Suite 310, High Point, NC 27265.
Filing Stats: 476 words · 2 min read · ~2 pages · Grade level 11.8 · Accepted 2024-10-25 16:29:55
Key Financial Figures
- $0.01 — stered Class A common stock, par value $0.01 per share VTVT Nasdaq Capital Market
Filing Documents
- vtvt-20241022.htm (8-K) — 22KB
- 0001641489-24-000069.txt ( ) — 142KB
- vtvt-20241022.xsd (EX-101.SCH) — 2KB
- vtvt-20241022_lab.xml (EX-101.LAB) — 21KB
- vtvt-20241022_pre.xml (EX-101.PRE) — 12KB
- vtvt-20241022_htm.xml (XML) — 3KB
02 Termination of a Material Definitive Agreement
Item 1.02 Termination of a Material Definitive Agreement On October 22, 2024, vTv Therapeutics LLC ("vTv LLC"), a controlled subsidiary of vTv Therapeutics Inc. (the "Company"), received notice from OnKure Therapeutics, formerly Reneo Pharmaceuticals, Inc. ("OnKure"), of their intent to terminate the License Agreement between vTv LLC and Reneo Pharmaceuticals, Inc., dated December 21, 2017, as amended December 20, 2021 (the "Agreement"). Under the Agreement, the Company had granted OnKure an exclusive, worldwide license to intellectual property pertaining to the Company's peroxisome proliferator-activated receptor delta (ppar-) agonist program. In its notice, OnKure indicated that it had decided to discontinue development of the program. Under the Agreement, the termination will become effective as of January 20, 2025.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. VTV THERAPEUTICS INC. By: /s/ Paul J. Sekhri Name: Paul J. Sekhri Title: President and Chief Executive Officer Dated: October 25, 2024